Xeris Biopharma Eyes High End Of FY21 Sales Outlook
Xeris Biopharma Holdings Inc (NASDAQ: XERS) has 
Benzinga · 1d ago
BRIEF-Xeris Biopharma Reaffirms 2021 Guidance And Provides Business Update · 1d ago
Xeris Biopharma reaffirms FY'21 guidance
Xeris Biopharma (NASDAQ:XERS) reaffirmed its 2021 pro forma net sales and year-end cash balance guidance. The company said preliminary 2021 full-year pro forma net sales at high-end of $76M-80M guidance,
Seekingalpha · 1d ago
Xeris Biopharma Reaffirms 2021 Guidance; Sees Prelim. FY21 Pro-Forma Net Sales At High End Of $76M-$80M Guidance
Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 preliminary cash, cash equivalents, and investments of approximately
Benzinga · 1d ago
PANTHERx Rare to distribute Xeris Biopharma's Recorlev for Cushing's syndrome
PANTHERx Rare has become the exclusive U.S. pharmacy distribution partner for Xeris Biopharma's (XERS +0.2%) recently approved medicine Recorlev (levoketoconazole) to treat Cushing's syndrome. Recorlev is a cortisol synthesis inhibitor indicated for the tr...
Seekingalpha · 6d ago
PANTHERx Rare Selected By Xeris Pharmaceuticals To Distribute Recorlev
PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazol...
Benzinga · 6d ago
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome
PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazol...
PR Newswire · 6d ago
Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Zacks · 01/07 15:13
BRIEF-Xeris Biopharma Enters Into Agreement For $30 Million Private Placement · 01/03 12:22
Xeris Biopharma to raise $30M in private placement offering
Xeris Biopharma (NASDAQ:XERS) trades 2.1% higher premarket after it entered into a securities purchase agreement related to a private placement with Armistice Capital affiliate for gross proceeds of ~$30M. The company will
Seekingalpha · 01/03 12:16
Hot Stocks: VORB plunges; XERS gets approval; NVAX vaccine supply worries; PEP, KO set highs
Wall Street ended a roaring 2021 with a whimper, with Friday's final day of the year ending with fractional losses. Stocks continued to hover just off their highs for the
Seekingalpha · 12/31/2021 22:30
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.
Benzinga · 12/31/2021 19:40
Mid-Afternoon Market Update: Dow Rises 50 Points; Nutriband Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.14% to 36,449.17 while the NASDAQ fell 0.20% to 15,710.56. The S&P also rose, gaining 0.08% to 4,782.32.
Benzinga · 12/31/2021 19:03
What 4 Analyst Ratings Have To Say About Xeris Biopharma Holdings
Analysts have provided the following ratings for Xeris Biopharma Holdings (NASDAQ:XERS) within the last quarter:
Benzinga · 12/31/2021 17:54
BBIO, SYTA and IMTE among mid-day movers
Gainers: Nutriband (NASDAQ:NTRB) +188%. Siyata Mobile (NASDAQ:SYTA) +36%. Medalist Diversified (NASDAQ:MDRR) +26%. uCloudlink (NASDAQ:UCL) +23%. Xeris Biopharma (NASDAQ:XERS) +22%. Biodesix (NASDAQ:BDSX) +22%. Dingdong Limited (NYSE:DDL) +18%. Lava Therape...
Seekingalpha · 12/31/2021 17:22
Mid-Day Market Update: Crude Oil Down 1%; Xeris Biopharma Shares Jump
Midway through trading Friday, the Dow traded down 0.08% to 36,370.19 while the NASDAQ fell 0.07% to 15,730.21. The S&P also fell, dropping 0.02% to 4,777.65.
Benzinga · 12/31/2021 17:07
21 Stocks Moving In Friday's Mid-Day Session
Benzinga · 12/31/2021 17:02
US STOCKS-Wall Street slips in choppy trade, set to clock robust yearly gains · 12/31/2021 16:00
Nutriband soars among healthcare gainers, Star Equity takes top loser tag
Gainers: Nutriband NTRB +184%. Nutriband (NTRBW) +134%. Xeris Biopharma (NASDAQ:XERS) +20%. Lava Therapeutics (NASDAQ:LVTX) +16%. Biodesix (NASDAQ:BDSX) +14%. Losers: Star Equity (NASDAQ:STRR) -17%. Kiora Pharmaceuticals (NASDAQ:KPRX) -14%. Spruce Bioscien...
Seekingalpha · 12/31/2021 16:00
Nutriband tops healthcare gainers; Star Equity among losers
Gainers: Nutriband NTRB +181%. Nutriband NTRBW +127%. Xeris Biopharma XERS +19%. Biodesix (NASDAQ:BDSX) +15%. Apollo Endosurgery (NASDAQ:APEN) +11%. Losers: Star Equity (NASDAQ:STRR) -17%. Kiora Pharmaceuticals (NASDAQ:KPRX) -16%. Spruce Biosciences. (NASD...
Seekingalpha · 12/31/2021 15:56
Webull provides a variety of real-time XERS stock news. You can receive the latest news about XERIS BIOPHARMA HOLDINGS INC through multiple platforms. This information may help you make smarter investment decisions.
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has two products, Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis, a therapy for primary periodic paralysis. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. The XeriSol formulation technology is suited for peptides and small molecules that encounter formulation challenges. The XeriJect formulation technology is suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.